Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00257478 · ClinicalTrials.gov registry record · Phase 2

A Study for the Treatment of Hormone Refractory Prostate Cancer (HRPC) in Patients Previously Treated With Chemotherapy

A Phase 2 study, sponsored by Astellas Pharma.

Completed
Registry status
Phase 2
Development phase

NCT00257478 is a Phase 2 study that has completed, run by Astellas Pharma.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00257478, a Phase 2 study, has completed, sponsored by Astellas Pharma.

COMPLETED
Registry status
Phase 2
Development phase

Study Summary

A study for the treatment of hormone refractory prostate cancer (HRPC) in patients previously treated with chemotherapy.

Interventions

  • DRUG YM155

Trial Details

FieldValue
Est. Completion 2007-03
Phase Phase 2

Sponsor

Astellas Pharma

165 total trials

What the Registry Record Tells You About NCT00257478

The ClinicalTrials.gov registry entry for NCT00257478 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which YM155 is the first listed.

NCT00257478 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00257478 about?

NCT00257478 is a clinical study titled "A Study for the Treatment of Hormone Refractory Prostate Cancer (HRPC) in Patients Previously Treated With Chemotherapy". A study for the treatment of hormone refractory prostate cancer (HRPC) in patients previously treated with chemotherapy.

What is the current status of trial NCT00257478?

This trial is currently completed. It is a Phase 2 study. Estimated completion is 2007-03.

What interventions are being tested in trial NCT00257478?

The interventions under investigation include: YM155 (DRUG).

Who is sponsoring clinical trial NCT00257478?

This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.